Home › NCT06744816
Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study
RecruitingEarly phase 1
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Participants diagnosed with pain of the lower extremity from chronic (\>90 days duration) CIPN (due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds), seen at MD Anderson Cancer Center * Participants reporting baseline pain ≥ 4 (0-10 scale, NRS) * Participants age 18+ * Participants who have completed chemotherapy within the last year at the time of enrollment. Exclusion Criteria: * Participants with cognitive dysfunction * Participants with recent history (\<6 months) of drug or alcohol abuse * Participants with open skin lesion or undergoing antibiotic therapy for local for systemic infection * Participants with allergies to capsaicin or adhesives * Pregnant participants
About the study
To learn if topical capsaicin can help relieve pain from CIPN and improve gait (the pattern of walking) in patients.
What is being tested
- Qutenza Patch (drug)
Sponsor: M.D. Anderson Cancer Center · Participants: 20 · Started: Dec 11, 2025
Contact the study team
- Saba Javed, MD · Phone: 713-792-9530
Official record on ClinicalTrials.gov — NCT06744816
Locations in the U.S.
| Texas | MD Anderson Cancer Center, Houston |
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.